By Narayanan Ramaswamy, head of advanced drug development at Tata Consultancy Services
Drug development remains one of the most complex, expensive, and time-consuming processes in any industry.
Across clinical trials, the biggest delays are often not caused by scientific uncertainty alone, but by operational bottlenecks, with industry data showing that 75 per cent of clinical trial protocols require at least one substantial amendment.
These amendments, alongside study setup, data review, submission preparation, and the monitoring and coordination required to keep everything compliant across teams and geographies, can create a costly drag on progress.
Manual, resource-heavy processes also slow timelines and make it harder for life sciences organisations to respond quickly to changing trial conditions. The result is a system that is too often constrained by human bandwidth rather than scientific potential.
AI agents are built for exactly this kind of work.
Rather than acting as isolated tools, they can work alongside scientists as a trusted digital workforce, taking on repeatable tasks across the clinical development lifecycle and helping teams move faster without losing sight of quality, oversight or compliance.
The biggest bottlenecks in drug development are operational
For healthcare professionals working in clinical development, the delays that matter most are often the ones that accumulate quietly in the background.
Protocol development is a clear example. Before a study can begin, teams may work through multiple drafts, reviews and alignments across clinical, regulatory, medical, safety and operational stakeholders.
The same applies to study setup. Sites need to be configured, data needs to be prepared and teams need to coordinate across multiple systems and geographies.
Submission preparation adds another layer of complexity, with large volumes of information needing to be turned into precise, compliant artefacts.
In each case, the challenge is not a lack of expertise. It is the amount of repetitive, document-heavy work required to keep everything moving.
How AI agents can accelerate the process
What sets AI agents apart from traditional software and standalone automation is adaptability.
They can interpret documents, respond to changing trial conditions and move between systems, while still operating within clearly defined roles.
That combination of flexibility and control makes them viable in regulated settings, where predictability and compliance are non-negotiable.
In practical terms, they can help with protocol drafting, data processing, submission artefact generation, monitoring support and pattern identification across clinical and operational data.
This reduces the manual effort required to prepare documents and helps teams’ surface relevant information faster.
The key is governance. AI cannot simply be dropped into a process and expected to work. It needs clear context of use, defined quality standards, supervision and lifecycle control.
That is the role of an AI agent hub.
The TCS ADD AgentHub, for example, is built to operate in governed, real-world clinical and pharmacovigilance environments, with trust, auditability and control designed in from the outset.
This is essential to drug development, where every output has to stand up to scrutiny.
What this means for the future of clinical teams
Today, many scientists and clinicians spend much of their time on preparatory and administrative work, such as reviewing report and managing handoffs. These are essential tasks, but they do not always make the best use of highly trained expertise.
By taking on repeatable work, AI agents can free people to focus more on judgement, insight and decision-making.
That means more time can be spent on scientific discovery and identifying risk and opportunity, and less on moving data through the process.
There is also a broader workforce implication. Life sciences organisations are under pressure from talent shortages, rising demand, and increasing regulatory complexity.
A trusted AI workforce can help create more elastic capacity, especially in areas where expert time is limited and demand can spike unexpectedly.
That does not reduce the importance of clinical teams. It makes their role more valuable.
As AI takes on more routine execution, human expertise becomes even more central in setting direction, reviewing exceptions and making the decisions that shape trial quality and patient outcomes.
A more scalable model for drug development
The ongoing digital transformation of the life sciences industry is helping to create well-connected, data-rich ecosystems and establish modern standards for clinical trial efficiency.
Now, AI agents are ready to put those investments to work.
Acting as a natural extension of existing automation tools, agents bring intelligent adaptability to regulated R&D environments, working across different digital systems to accelerate protocol drafting, data review, and regulatory submissions.
The future of drug development will involve people and AI workers collaborating much more closely, with agents taking on defined tasks and humans focusing on the work that requires clinical, scientific, and regulatory judgement.
This is the direction the industry is moving in, not AI as an isolated tool, but AI as part of a governed digital workforce that can help life sciences organisations scale with greater confidence and get treatments to patients faster.
